高泌乳素血症性不孕症的临床研究进展
Clinical Research Progress of Hyperprolactinemic Infertility
DOI: 10.12677/ACM.2022.121014, PDF,    国家自然科学基金支持
作者: 周礼香, 王 旭:大理大学临床医学院,云南 大理;张若鹏*:大理大学第一附属医院,云南 大理
关键词: 高泌乳素血症不孕症垂体泌乳素瘤Hyperprolactinemia Infertility Pituitary Prolactinoma
摘要: 不孕症(infertility)是最常见的妇科疾病之一。我国育龄夫妇中,8.5%~20%的妇女患有不孕症,该症对患者及其家庭造成了极大的不良影响。女性不孕症患者中,高泌乳素血症(hyperprolactinemia, HPRL)的患病率高达15%~20%,HPRL被认为是引起育龄妇女不孕的重要原因。而目前临床上关于高泌乳素血症性不孕症的发病机制及诊疗方案还有待深入研究,探寻更多的证据。有望使提升高泌乳素血症性不孕症的诊疗水平和改善患者心理健康及生活质量成为可能。本文将从HPRL性不孕症的病因、发病机制、诊断和治疗等方面进行综述,阐明该病的研究现状及对未来提出展望。
Abstract: Infertility is one of the most common gynecological diseases. Among couples of childbearing age in China, 8.5%~20% of women suffer from infertility, which has caused great adverse effects on patients and their families. Among female infertility patients, the prevalence of hyperprolactinemia (HPRL) is as high as 15%~20%, and HPRL is considered to be an important cause of infertility in women of childbearing age. At present, the pathogenesis, diagnosis and treatment of HPRL infertility need to be further studied to explore more evidence. It is expected to improve the diagnosis and treatment level of HPRL infertility and improve the mental health and quality of life of patients. In this paper, the etiology, pathogenesis, diagnosis and treatment of HPRL infertility were reviewed, and the research status of this disease was clarified and the prospects for the future were put forward.
文章引用:周礼香, 王旭, 张若鹏. 高泌乳素血症性不孕症的临床研究进展[J]. 临床医学进展, 2022, 12(1): 78-84. https://doi.org/10.12677/ACM.2022.121014

参考文献

[1] 周红娟, 庞书勤, 葛莉, 等. 不孕症患者心理韧性与生育生活质量的相关性分析[J]. 医学理论与实践, 2020, 33(19): 3309-3311.
[2] 高丹凤, 成佳景, 宋力雯, 等. 内分泌失调所致不孕症与高泌乳血症的相关性[J]. 山西医药杂志, 2017, 46(17): 2100-2102.
[3] 黄荷凤, 王波, 朱依敏. 不孕症发生现状及趋势分析[J]. 中国实用妇科与产科杂志, 2013, 29(9): 688-690.
[4] 李玉. 高泌乳素血症研究进展[J]. 淮北职业技术学院学报, 2019, 18(2): 108-110+13.
[5] 康世眉, 陆杉, 刘路. 高泌乳素血症与不孕症关系的探讨[J]. 广西医科大学学报, 2002, 19(1): 49-51.
[6] Cabrera-Reyes, E.A., Limon-Morales, O., Rivero-Segura, N.A., et al. (2017) Prolactin Function and Putative Expression in the Brain. Endocrine, 57,199-213. [Google Scholar] [CrossRef] [PubMed]
[7] Bernard, V., Young, J. and Binart, N. (2019) Prolactin—A Pleiotropic Factor in Health and Disease. Nature Reviews Endocrinology, 15, 356-365. [Google Scholar] [CrossRef] [PubMed]
[8] Garcia-Rizo, C., Vazquez-Bourgon, J., Labad, J., et al. (2021) Prolactin, Metabolic and Immune Parameters in Naive Subjects with a First Episode of Psychosis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 110, Article ID: 110332. [Google Scholar] [CrossRef] [PubMed]
[9] Pathipati, P., Gorba, T., Scheepens, A., et al. (2011) Growth Hormone and Prolactin Regulate Human Neural Stem Cell Regenerative Activity. Neuroscience, 190, 409-427. [Google Scholar] [CrossRef] [PubMed]
[10] 女性高催乳素血症诊治共识[J]. 中华妇产科杂志, 2016, 51(3): 161-168.
[11] Markin, L.B., Shatylovych, K.L. and Semenyna, Н.B. (2019) Prevention of Miscarriage Following Ovulation Induction in Women with Endocrine Infertility in Anamnesis. Zaporozhye Medical Journal, 21, 484-490. [Google Scholar] [CrossRef
[12] 喻长法, 张仙森, 李香娟, 等. 高泌乳素血症与不孕的相关性研究[J]. 中国优生与遗传杂志, 2009, 17(4): 121.
[13] Lee, I., Son, D.W., Park, J.H., et al. (2021) Drug-Induced Hyperprolactinemia Results in a Typical Fracture. Hip & Pelvis, 33, 102-107. [Google Scholar] [CrossRef] [PubMed]
[14] 孔令伶俐, 许良智. 高泌乳素血症的病因学[J]. 实用妇产科杂志, 2016, 32(7): 481-483.
[15] 徐婷, 丁丽仙, 邹彩霞. 丁丽仙教授治疗高催乳素血症月经过少验案举隅[J]. 实用妇科内分泌电子杂志, 2019, 6(26): 115-116.
[16] 王佳宁, 阮祥燕. 高泌乳素血症的病因及诊疗进展[J]. 医学综述, 2012, 18(21): 3629-3632.
[17] 黄世英, 付景云, 李红. 高泌乳素血症与代谢综合征的相关性研究进展[J]. 中国医药指南, 2013, 11(35): 350-351.
[18] Muzaffar, A. and Lubna, M. (2021) Morbid Obesity due to Prolactinoma and Significant Weight Loss after Dopamine Agonist Treatment. AACE Clinical Case Reports, 7, 204-206. [Google Scholar] [CrossRef] [PubMed]
[19] Capozzi, A., Scambia, G., Pontecorvi, A., et al. (2015) Hyperprolactinemia: Pathophysiology and Therapeutic Approach. Gynecological Endocrinology, 31, 506-510. [Google Scholar] [CrossRef] [PubMed]
[20] Venkatanarasu, A., Boddula, R., Basavaraju, S., et al. (2021) Drug Induced Hyperprolactinemia. Journal of the Endocrine Society, 5, A626-A627. [Google Scholar] [CrossRef
[21] Ignacak, A., et al. (2012) Prolactin—Not Only Lactotrophin. A “New” View of the “Old” Hormone. Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society, 63, 435-443.
[22] Vilar, L., Abucham, J., Albuquerque, J.L., et al. (2018) Controversial Issues in the Management of Hyperprolactinemia and Prolactinomas—An Overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 62, 236-263. [Google Scholar] [CrossRef] [PubMed]
[23] 袁洪波, 张伶俐, 杨春松, 等. 中国女性患者溴隐亭阴道给药治疗高催乳素血症有效性和安全性的Meta分析[J]. 中国药房, 2018, 29(1): 111-116.
[24] 王娟, 阮祥燕, 殷冬梅, 等. 溴隐亭不同给药方案治疗高泌乳素血症女性性腺激素促排卵临床研究[J]. 现代生物医学进展, 2017, 17(1): 130-132+44.
[25] Ratner, L.D., Stevens, G., Bonaventura, M.M., et al. (2016) Hyperprolactinemia Induced by hCG Leads to Metabolic Disturbances in Female Mice. Journal of Endocrinology, 230, 157-169. [Google Scholar] [CrossRef
[26] 吴汉杰, 莫翠玲. 经不同给药方式使用溴隐亭治疗高泌乳素血症所致不孕症的效果对比[J]. 当代医药论丛, 2020, 18(13): 44-46.
[27] 施静, 杨帆. 溴隐亭在促排卵治疗中的应用[J]. 中国新药与临床杂志, 2014, 33(3): 164-167.
[28] 刘雪燕. 溴隐亭治疗高泌乳素血症所致不孕症的临床研究[J]. 中国医学创新, 2011, 8(34): 151-152.
[29] 张鹏. 不同促排卵时机对溴隐亭治疗高泌乳素血症患者的影响[J]. 中国当代医药, 2019, 26(23): 143-145.
[30] 晏源. 溴隐亭治疗女性高泌乳素血症性不孕临床效果[J]. 中国继续医学教育, 2019, 11(19): 118-120.
[31] 葛秋燕. 溴隐亭口服与阴道放置治疗高泌乳素血症不孕临床研究[J]. 实用妇科内分泌杂志(电子版), 2018, 5(28): 48-49.
[32] 王佳, 张婧芳. 溴隐亭不同给药方式对高泌乳素血症伴不孕症患者的影响[J]. 深圳中西医结合杂志, 2021, 31(5): 141-143.
[33] 黄瑾翔. 经鼻蝶入路鞍区占位切除术治疗伴高泌乳素血症无功能垂体腺瘤的疗效[J]. 第二军医大学学报, 2020, 41(10): 1084-1090.
[34] Glezer, A. and Bronstein, M.D. (2020) Prolactinomas in Pregnancy: Considerations before Conception and during Pregnancy. Pituitary: The Official Journal of the Pituitary Society, 23, 65-69. [Google Scholar] [CrossRef] [PubMed]
[35] 周姗姗, 高彩霞, 张新霞. 高泌乳素血症的中西医治疗进展[J]. 世界最新医学信息文摘, 2017, 17(68): 52-53+6.
[36] 卢恒, 梁卓. 高泌乳血症的中医药研究进展[J]. 中医临床研究, 2017, 9(22): 147-148.